FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802662564> ?p ?o ?g. }

• W2802662564 endingPage "5077" @default.
• W2802662564 startingPage "5063" @default.
• W2802662564 abstract "mAbs have emerged as a promising strategy for the treatment of cancer. However, in several malignancies, no effective antitumor mAbs are yet available. Identifying therapeutic mAbs that recognize common tumor antigens could render the treatment widely applicable. Here, a human single-chain variable fragment (scFv) antibody library was sequentially affinity selected against a panel of human cancer cell lines and an antibody fragment (named MS5) that bound to solid and blood cancer cells was identified. The MS5 scFv was fused to the human IgG1 Fc domain to generate an antibody (MS5-Fc fusion) that induced antibody-dependent cellular cytotoxicity and phagocytosis of cancer cells by macrophages. In addition, the MS5-Fc antibody bound to primary leukemia cells and induced antibody-dependent cellular cytotoxicity. In the majority of analyzed cancer cells, the MS5-Fc antibody induced cell surface redistribution of the receptor complexes, but not internalization, thus maximizing the accessibility of the IgG1 Fc domain to immune effector cells. In vitro stability studies showed that the MS5-Fc antibody was stable after 6 d of incubation in human serum, retaining ∼60% of its initial intact form. After intravenous injections, the antibody localized into tumor tissues and inhibited the growth of 3 different human tumor xenografts (breast, lymphoma, and leukemia). These antitumor effects were associated with tumor infiltration by macrophages and NK cells. In the Ramos B-cell lymphoma xenograft model, the MS5-Fc antibody exhibited a comparable antitumor effect as rituximab, a chimeric anti-CD20 IgG1 mAb. These results indicate that human antibodies with pan-cancer abilities can be generated from phage display libraries, and that the engineered MS5-Fc antibody could be an attractive agent for further clinical investigation.-Sioud, M., Westby, P., Vasovic, V., Fløisand, Y., Peng, Q. Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies." @default.
• W2802662564 created "2018-05-17" @default.
• W2802662564 creator A5006395020 @default.
• W2802662564 creator A5009384641 @default.
• W2802662564 creator A5024811171 @default.
• W2802662564 creator A5036557609 @default.
• W2802662564 creator A5088648316 @default.
• W2802662564 date "2018-04-16" @default.
• W2802662564 modified "2023-09-25" @default.
• W2802662564 title "Development of a new high‐affinity human antibody with antitumor activity against solid and blood malignancies" @default.
• W2802662564 cites W1606431180 @default.
• W2802662564 cites W1915689252 @default.
• W2802662564 cites W1963777403 @default.
• W2802662564 cites W1965302158 @default.
• W2802662564 cites W1978755540 @default.
• W2802662564 cites W1984381148 @default.
• W2802662564 cites W1989422685 @default.
• W2802662564 cites W1993160668 @default.
• W2802662564 cites W2009109361 @default.
• W2802662564 cites W2010329820 @default.
• W2802662564 cites W2022069273 @default.
• W2802662564 cites W2033577259 @default.
• W2802662564 cites W2049553585 @default.
• W2802662564 cites W2050628678 @default.
• W2802662564 cites W2053981824 @default.
• W2802662564 cites W2079130077 @default.
• W2802662564 cites W2089036873 @default.
• W2802662564 cites W2091229935 @default.
• W2802662564 cites W2104885590 @default.
• W2802662564 cites W2106481926 @default.
• W2802662564 cites W2127084226 @default.
• W2802662564 cites W2134487724 @default.
• W2802662564 cites W2143562636 @default.
• W2802662564 cites W2146143166 @default.
• W2802662564 cites W2147210428 @default.
• W2802662564 cites W2160264356 @default.
• W2802662564 cites W2162308516 @default.
• W2802662564 cites W2209221218 @default.
• W2802662564 cites W2264636885 @default.
• W2802662564 cites W2345568581 @default.
• W2802662564 cites W2401140130 @default.
• W2802662564 cites W2403301106 @default.
• W2802662564 cites W2469758901 @default.
• W2802662564 cites W2474739399 @default.
• W2802662564 cites W2474760928 @default.
• W2802662564 cites W2747415234 @default.
• W2802662564 cites W2793688554 @default.
• W2802662564 doi "https://doi.org/10.1096/fj.201701544r" @default.
• W2802662564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29913558" @default.
• W2802662564 hasPublicationYear "2018" @default.
• W2802662564 type Work @default.
• W2802662564 sameAs 2802662564 @default.
• W2802662564 citedByCount "7" @default.
• W2802662564 countsByYear W28026625642019 @default.
• W2802662564 countsByYear W28026625642020 @default.
• W2802662564 countsByYear W28026625642021 @default.
• W2802662564 countsByYear W28026625642022 @default.
• W2802662564 countsByYear W28026625642023 @default.
• W2802662564 crossrefType "journal-article" @default.
• W2802662564 hasAuthorship W2802662564A5006395020 @default.
• W2802662564 hasAuthorship W2802662564A5009384641 @default.
• W2802662564 hasAuthorship W2802662564A5024811171 @default.
• W2802662564 hasAuthorship W2802662564A5036557609 @default.
• W2802662564 hasAuthorship W2802662564A5088648316 @default.
• W2802662564 hasBestOaLocation W28026625641 @default.
• W2802662564 hasConcept C109316439 @default.
• W2802662564 hasConcept C115085202 @default.
• W2802662564 hasConcept C121608353 @default.
• W2802662564 hasConcept C147483822 @default.
• W2802662564 hasConcept C159654299 @default.
• W2802662564 hasConcept C18031839 @default.
• W2802662564 hasConcept C185592680 @default.
• W2802662564 hasConcept C202751555 @default.
• W2802662564 hasConcept C203014093 @default.
• W2802662564 hasConcept C2777092746 @default.
• W2802662564 hasConcept C2778461978 @default.
• W2802662564 hasConcept C40677261 @default.
• W2802662564 hasConcept C502942594 @default.
• W2802662564 hasConcept C542903549 @default.
• W2802662564 hasConcept C54355233 @default.
• W2802662564 hasConcept C55493867 @default.
• W2802662564 hasConcept C86803240 @default.
• W2802662564 hasConcept C96232424 @default.
• W2802662564 hasConceptScore W2802662564C109316439 @default.
• W2802662564 hasConceptScore W2802662564C115085202 @default.
• W2802662564 hasConceptScore W2802662564C121608353 @default.
• W2802662564 hasConceptScore W2802662564C147483822 @default.
• W2802662564 hasConceptScore W2802662564C159654299 @default.
• W2802662564 hasConceptScore W2802662564C18031839 @default.
• W2802662564 hasConceptScore W2802662564C185592680 @default.
• W2802662564 hasConceptScore W2802662564C202751555 @default.
• W2802662564 hasConceptScore W2802662564C203014093 @default.
• W2802662564 hasConceptScore W2802662564C2777092746 @default.
• W2802662564 hasConceptScore W2802662564C2778461978 @default.
• W2802662564 hasConceptScore W2802662564C40677261 @default.
• W2802662564 hasConceptScore W2802662564C502942594 @default.
• W2802662564 hasConceptScore W2802662564C542903549 @default.
• W2802662564 hasConceptScore W2802662564C54355233 @default.

• next